NextCure  Inc (NXTC)

NASDAQ
5.070
-0.080(-1.55%)
  • Volume:
    581,541
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    4.930 - 5.150

NXTC Overview

Prev. Close
5.15
Day's Range
4.93-5.15
Revenue
-
Open
5.1
52 wk Range
4.93-14.4
EPS
-2.46
Volume
581,541
Market Cap
140.06M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
261,106
P/E Ratio
-
Beta
-
1-Year Change
-62.13%
Shares Outstanding
27,626,227
Next Earnings Date
Mar 17, 2022
What is your sentiment on NextCure  Inc?
or
Market is currently closed. Voting is open during market hours.

NextCure  Inc Company Profile

Employees
90

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong SellStrong SellStrong Sell
  • Whats the story on this company? I just bought in at $9.27. Its been hit hard but maybe due for a comeback?
    1
    • lol
      0
      • glad u r laughing ! I am LOL now, since I can buy it this cheap now
        0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.